These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22018617)

  • 21. Safety of subcutaneous immunotherapy with inhalant allergen extracts: a single-center 30-year experience from Turkey.
    Kartal O; Gulec M; Caliskaner Z; Musabak U; Sener O
    Immunopharmacol Immunotoxicol; 2015 Jun; 37(3):280-6. PubMed ID: 25858053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic reactions due to allergen immunotherapy.
    Karaayvaz M; Erel F; Caliskaner Z; Ozangüç N
    J Investig Allergol Clin Immunol; 1999; 9(1):39-44. PubMed ID: 10212856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonfatal systemic allergic reactions induced by skin testing and immunotherapy.
    Lin MS; Tanner E; Lynn J; Friday GA
    Ann Allergy; 1993 Dec; 71(6):557-62. PubMed ID: 8267250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The safety of allergen immunotherapy: a literature review.
    Cook PR; Farias C
    Ear Nose Throat J; 1998 May; 77(5):378-9, 383-8. PubMed ID: 9615518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Local reactions during allergen immunotherapy do not require dose adjustment.
    Tankersley MS; Butler KK; Butler WK; Goetz DW
    J Allergy Clin Immunol; 2000 Nov; 106(5):840-3. PubMed ID: 11080704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Evaluation of the pediatric aspects of the WHO document and meta-analysis of immunotherapy].
    Ibáñez Sendín MD
    Allergol Immunopathol (Madr); 2000; 28(3):82-9. PubMed ID: 10867375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative study of cluster and conventional immunotherapy schedules with dermatophagoides pteronyssinus in the treatment of persistent allergic rhinitis.
    Zhang L; Wang C; Han D; Wang X; Zhao Y; Liu J
    Int Arch Allergy Immunol; 2009; 148(2):161-9. PubMed ID: 18802361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subcutaneous immunotherapy in Northern Israel: efficacy and safety.
    Rottem M; Egbarya A
    Isr Med Assoc J; 2014 Sep; 16(9):539-43. PubMed ID: 25351009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Side-effects of injective allergen immunotherapy administered to intermittent or persistent allergic rhinitis patients.
    Rogala B; Markiewicz-Bendkowska IB; Brzoza Z; Glück J; Oleś E
    Rhinology; 2007 Jun; 45(2):134-9. PubMed ID: 17708460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of two cluster schedules for subcutaneous immunotherapy in allergic rhinitis or asthma patients sensitized to inhalant allergens.
    Pfaar O; Klimek L; Fischer I; Sieber J; Amoroso S; Moreno Aguilar C; Shah K; Mösges R
    Int Arch Allergy Immunol; 2009; 150(1):102-8. PubMed ID: 19339808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy units: a follow-up study.
    Machín IS; Robaina JCG ; Bonnet C; de Blas C; Fernández-Caldas E; Triviño MS; de la Morin FT
    J Investig Allergol Clin Immunol; 2001; 11(3):167-71. PubMed ID: 11831448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Preventive immunotherapy].
    Boquete M; Carballada F; Expósito F; González A
    Allergol Immunopathol (Madr); 2000; 28(3):89-93. PubMed ID: 10867376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors for systemic reactions to allergen immunotherapy.
    Iglesias-Cadarso A; Hernández-Weigand P
    Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):579-85. PubMed ID: 21971329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of allergen immunotherapy in the treatment of allergic rhinitis and asthma in real life.
    Zeldin Y; Weiler Z; Magen E; Tiosano L; Kidon MI
    Isr Med Assoc J; 2008 Dec; 10(12):869-72. PubMed ID: 19160945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Knowledge and expectations of patients receiving aeroallergen immunotherapy.
    Sade K; Berkun Y; Dolev Z; Shalit M; Kivity S
    Ann Allergy Asthma Immunol; 2003 Nov; 91(5):444-8. PubMed ID: 14692426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Flexible approaches in the design of subcutaneous immunotherapy protocols for Hymenoptera venom allergy.
    Alessandrini AE; Berra D; Rizzini FL; Mauro M; Melchiorre A; Rossi F; Spezia D; Stanizzi R; Ricciardi L; Burastero SE
    Ann Allergy Asthma Immunol; 2006 Jul; 97(1):92-7. PubMed ID: 16892788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of systemic allergic reactions to allergen immunotherapy in a pediatric allergy clinic in Turkey.
    Bahceci Erdem S; Nacaroglu HT; Karaman S; Unsal Karkıner CS; Gunay I; Dogan D; Asilsoy S; Altınoz S; Can D
    Int J Pediatr Otorhinolaryngol; 2016 May; 84():55-60. PubMed ID: 27063754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus.
    Tabar AI; Echechipía S; García BE; Olaguibel JM; Lizaso MT; Gómez B; Aldunate MT; Martin S; Marcotegui F
    J Allergy Clin Immunol; 2005 Jul; 116(1):109-18. PubMed ID: 15990782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors associated with non-adherence to specific allergen immunotherapy in management of respiratory allergy.
    Mahesh PA; Vedanthan PK; Amrutha DH; Giridhar BH; Prabhakar AK
    Indian J Chest Dis Allied Sci; 2010; 52(2):91-5. PubMed ID: 20578401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors for adverse systemic reactions occurring during immunotherapy with standardized Dermatophagoides farinae extracts.
    Ohashi Y; Nakai Y; Tanaka A; Kakinoki Y; Washio Y; Ohno Y; Yamada K; Nasako Y
    Acta Otolaryngol Suppl; 1998; 538():113-7. PubMed ID: 9879410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.